Current Home Office guidance around CBD products is “difficult to interpret”, said NPA head of advice and support services Jasmine Shah.
Clearer guidance would make it “easier for manufacturers, healthcare professionals, retailers and customer [t stay] on the right side of the law and safe from harm”, she said last week.
The NPA advises pharmacists to “ensure they are acting legally and in the best interest of patients – which is the same advice we give all other products sold or supplied in pharmacies”, she added.
Ms Shah appeared on BBC News on December 12, where she said “more research is required” on CBD products and that it is “up to each individual” to decide whether they stock them or not.
RPS: Limited evidence for clinical use of CBD
Current guidance by the Royal Pharmaceutical Society states that there is “limited evidence on the clinical uses of CBD”.
It also outlines that the terms “cannabis oil” and “CBD oil” have no legal definitions, and “may cause confusion”.
For more information on selling CBD products in your pharmacy, advising patients on their use and the difference between CBD and medicinal cannabis, read C+D’s in-depth analysis.